What is Xact Laboratories?
Xact Laboratories operates at the intersection of biotechnology and health informatics, specializing in patented pharmacogenomic (PGx) technology. The company's core value proposition lies in its automated medication safety platform, which is engineered to intercept potentially harmful prescriptions before they reach the patient. By delivering real-time genetic data directly into electronic health record (EHR) systems, Xact Laboratories empowers clinicians to make informed, data-driven decisions that mitigate the risk of adverse drug reactions. This technological infrastructure is designed to enhance medication adherence and optimize therapeutic efficacy across diverse patient populations, positioning the firm as a critical partner for healthcare providers aiming to reduce systemic costs while improving clinical outcomes.
How much funding has Xact Laboratories raised?
Xact Laboratories has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Xact Laboratories
PPP
Public-Private Partnership
What's next for Xact Laboratories?
With this recent infusion of capital, Xact Laboratories is poised to scale its operational footprint and deepen its penetration within the healthcare provider market. The strategic focus will likely shift toward expanding the integration capabilities of its PGx platform, ensuring seamless interoperability with a broader array of EHR systems. As the industry moves toward more personalized treatment paradigms, the company's ability to provide actionable, real-time insights will be a key differentiator. Future growth initiatives will likely prioritize the enhancement of its testing suite and the pursuit of strategic partnerships with large-scale health systems, further cementing its status as a leader in the medication safety sector.
See full Xact Laboratories company page
